INTRODUCTION: In breast cancer, the metastatic process may involve the dissemination of circulating tumour cells (CTCs) through the blood and lymphatic system prior to the colonisation of distant organs. Here we demonstrate the predictive capacity of CTCs for detecting risk of death in breast cancer patients during established time intervals. METHODS: CTCs were identified by immunocytochemical methods following isolation by selective immunomagnetic cell separation of cytokeratin-positive cells. Serial blood samples from 65 patients were collected at roughly monthly intervals for up to 50 months. Follow-up was conducted at different intervals: 1-5, >5-12, >12-24 and >24-50 months. RESULTS: Both presence and number of CTCs were correlated to risk of death: patients with CTCs at any time during follow-up had a higher risk of death (p=0.035) than patients without CTCs. Furthermore, during the first 5 months of therapy, patients with >5 CTCs had a higher risk of death than patients with <5 CTCs (p=0.002). CONCLUSIONS: Our results show that the persistence of CTCs after chemotherapy, particularly during the first 5 months, could define a group of patients with a high risk of relapse.
INTRODUCTION: In breast cancer, the metastatic process may involve the dissemination of circulating tumour cells (CTCs) through the blood and lymphatic system prior to the colonisation of distant organs. Here we demonstrate the predictive capacity of CTCs for detecting risk of death in breast cancerpatients during established time intervals. METHODS:CTCs were identified by immunocytochemical methods following isolation by selective immunomagnetic cell separation of cytokeratin-positive cells. Serial blood samples from 65 patients were collected at roughly monthly intervals for up to 50 months. Follow-up was conducted at different intervals: 1-5, >5-12, >12-24 and >24-50 months. RESULTS: Both presence and number of CTCs were correlated to risk of death: patients with CTCs at any time during follow-up had a higher risk of death (p=0.035) than patients without CTCs. Furthermore, during the first 5 months of therapy, patients with >5 CTCs had a higher risk of death than patients with <5 CTCs (p=0.002). CONCLUSIONS: Our results show that the persistence of CTCs after chemotherapy, particularly during the first 5 months, could define a group of patients with a high risk of relapse.
Authors: Daniel F Hayes; Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; M Craig Miller; Jeri Matera; W Jeffrey Allard; Gerald V Doyle; Leon W W M Terstappen Journal: Clin Cancer Res Date: 2006-07-15 Impact factor: 12.531
Authors: P Rudolph; G MacGrogan; F Bonichon; S O Frahm; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre; R Parwaresch Journal: Breast Cancer Res Treat Date: 1999-05 Impact factor: 4.872
Authors: Stephan Braun; Florian D Vogl; Bjørn Naume; Wolfgang Janni; Michael P Osborne; R Charles Coombes; Günter Schlimok; Ingo J Diel; Bernd Gerber; Gerhard Gebauer; Jean-Yves Pierga; Christian Marth; Daniel Oruzio; Gro Wiedswang; Erich-Franz Solomayer; Günther Kundt; Barbara Strobl; Tanja Fehm; George Y C Wong; Judith Bliss; Anne Vincent-Salomon; Klaus Pantel Journal: N Engl J Med Date: 2005-08-25 Impact factor: 91.245
Authors: Pia Wülfing; Julia Borchard; Horst Buerger; Stefan Heidl; Kurt S Zänker; Ludwig Kiesel; Burkhard Brandt Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: N Xenidis; I Vlachonikolis; D Mavroudis; M Perraki; A Stathopoulou; N Malamos; C Kouroussis; S Kakolyris; S Apostolaki; N Vardakis; E Lianidou; V Georgoulias Journal: Ann Oncol Date: 2003-06 Impact factor: 32.976
Authors: Annalisa Gervasoni; Rina M Monasterio Muñoz; Georg S Wengler; Anna Rizzi; Alberto Zaniboni; Ornella Parolini Journal: Cancer Lett Date: 2008-02-08 Impact factor: 8.679
Authors: Christian Schindlbeck; Theresa Kampik; Wolfgang Janni; Brigitte Rack; Udo Jeschke; Stan Krajewski; Harald Sommer; Klaus Friese Journal: Breast Cancer Res Date: 2005-11-24 Impact factor: 6.466
Authors: María José Serrano; Pedro Sánchez Rovira; I Martínez-Zubiaurre; Miguel Delgado Rodriguez; Mónica Fernández; Jose A Lorente Journal: Exp Ther Med Date: 2012-04-05 Impact factor: 2.447
Authors: Alba Rodríguez-Martínez; Diego de Miguel-Pérez; Francisco Gabriel Ortega; José Luis García-Puche; Inmaculada Robles-Fernández; José Exposito; Jordi Martorell-Marugan; Pedro Carmona-Sáez; María Del Carmen Garrido-Navas; Christian Rolfo; Hugh Ilyine; José Antonio Lorente; Marta Legueren; María José Serrano Journal: Breast Cancer Res Date: 2019-02-06 Impact factor: 6.466